FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056547069> ?p ?o ?g. }

• W2056547069 endingPage "8125" @default.
• W2056547069 startingPage "8118" @default.
• W2056547069 abstract "The MAPKKs MEK1 and MEK2 are activated by phosphorylation, but little is known about how these enzymes are inactivated. Here, we show that MEK1 is phosphorylated in vivo at Ser212, a residue conserved among all MAPKK family members. Mutation of Ser212 to alanine enhanced the basal activity of MEK1, whereas the phosphomimetic aspartate mutation completely suppressed the activation of both wild-type MEK1 and the constitutively activated MEK1(S218D/S222D) mutant. Phosphorylation of Ser212 did not interfere with activating phosphorylation of MEK1 at Ser218/Ser222 or with binding to ERK2 substrate. Importantly, mimicking phosphorylation of the equivalent Ser212 residue of the yeast MAPKKs Pbs2p and Ste7p similarly abrogated their biological function. Our findings suggest that Ser212 phosphorylation represents an evolutionarily conserved mechanism involved in the negative regulation of MAPKKs. The MAPKKs MEK1 and MEK2 are activated by phosphorylation, but little is known about how these enzymes are inactivated. Here, we show that MEK1 is phosphorylated in vivo at Ser212, a residue conserved among all MAPKK family members. Mutation of Ser212 to alanine enhanced the basal activity of MEK1, whereas the phosphomimetic aspartate mutation completely suppressed the activation of both wild-type MEK1 and the constitutively activated MEK1(S218D/S222D) mutant. Phosphorylation of Ser212 did not interfere with activating phosphorylation of MEK1 at Ser218/Ser222 or with binding to ERK2 substrate. Importantly, mimicking phosphorylation of the equivalent Ser212 residue of the yeast MAPKKs Pbs2p and Ste7p similarly abrogated their biological function. Our findings suggest that Ser212 phosphorylation represents an evolutionarily conserved mechanism involved in the negative regulation of MAPKKs. mitogen-activated protein kinase mitogen-activated protein kinase kinase mitogen-activated protein kinase kinase kinase extracellular signal-regulated kinase mitogen-activated protein kinase/extracellular signal-regulated kinase kinase human embryonic kidney hemagglutinin high performance liquid chromatography glutathioneS-transferase high osmolarity glycerol Mitogen-activated protein kinase (MAPK)1 pathways are evolutionarily conserved signaling modules by which cells transduce extracellular chemical and physical signals into intracellular responses (reviewed in Refs. 1Lewis T.S. Shapiro P.S. Ahn N.G. Adv. Cancer Res. 1998; 74: 49-139Google Scholar, 2Widmann C. Gibson S. Jarpe M.B. Johnson G.L. Physiol. Rev. 1999; 79: 143-180Google Scholar, 3Pearson G. Robinson F. Beers Gibson T. Xu B.E. Karandikar M. Berman K. Cobb M.H. Endocr. Rev. 2001; 22: 153-183Google Scholar). These modules are organized into an architecture of three sequentially acting protein kinases comprising a MAPK kinase kinase (MAPKKK or MEK kinase), a MAPK kinase (MAPKK or MEK), and the MAPK itself. The propagation of the signal through MAPK pathways is facilitated by specific protein-protein interactions between individual components of the pathway and scaffolding proteins (3Pearson G. Robinson F. Beers Gibson T. Xu B.E. Karandikar M. Berman K. Cobb M.H. Endocr. Rev. 2001; 22: 153-183Google Scholar, 4Schaeffer H.J. Weber M.J. Mol. Cell. Biol. 1999; 19: 2435-2444Google Scholar). The prototypical and most studied MAPK pathway is the ERK1/2 pathway, which controls cell proliferation, differentiation, and development (1Lewis T.S. Shapiro P.S. Ahn N.G. Adv. Cancer Res. 1998; 74: 49-139Google Scholar). Stimulation of cells with growth and differentiation factors leads to the activation of the MAPKKK Raf by a complicated mechanism involving cellular relocalization and multiple phosphorylation events (5Morrison D.K. Cutler R.E. Curr. Opin. Cell Biol. 1997; 9: 174-179Google Scholar, 6Kolch W. Biochem. J. 2000; 351: 289-305Google Scholar). Activated Raf isoforms bind to and activate the MAPKKs MEK1 and MEK2 by phosphorylation of two serine residues (corresponding to Ser218 and Ser222 in MEK1) in their activation loop (7Alessi D.R. Saito Y. Campbell D.G. Cohen P. Sithanandam G. Rapp U. Ashworth A. Marshall C.J. Cowley S. EMBO J. 1994; 13: 1610-1619Google Scholar, 8Zheng C.F. Guan K.-L. EMBO J. 1994; 13: 1123-1131Google Scholar). Substitution of the two regulatory serines with acidic residues is sufficient to enhance the basal activity of MEK1/2 (7Alessi D.R. Saito Y. Campbell D.G. Cohen P. Sithanandam G. Rapp U. Ashworth A. Marshall C.J. Cowley S. EMBO J. 1994; 13: 1610-1619Google Scholar, 8Zheng C.F. Guan K.-L. EMBO J. 1994; 13: 1123-1131Google Scholar, 9Gotoh Y. Matsuda S. Takenaka K. Hattori S. Iwamatsu A. Ishikawa M. Kosako H. Nishida E. Oncogene. 1994; 9: 1891-1898Google Scholar, 10Pages G. Brunet A. L'Allemain G. Pouyssegur J. EMBO J. 1994; 13: 3003-3010Google Scholar, 11Huang W. Erikson R.L. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 8960-8963Google Scholar, 12Mansour S.J. Matten W.T. Hermann A.S. Candia J.M. Rong S. Fukasawa K. Vande Woude G.F. Ahn N.G. Science. 1994; 265: 966-970Google Scholar). The dual-specificity kinases MEK1 and MEK2 then catalyze the phosphorylation of the MAPKs ERK1 and ERK2 at threonine and tyrosine residues within the activation loop motif Thr-Glu-Tyr (13Payne D.M. Rossomando A.J. Martino P. Erickson A.K. Her J.H. Shabanowitz J. Hunt D.F. Weber M.J. Sturgill T.W. EMBO J. 1991; 10: 885-892Google Scholar), causing a reorientation of the loop and activation of the enzyme (14Canagarajah B.J. Khokhlatchev A. Cobb M.H. Goldsmith E.J. Cell. 1997; 90: 859-869Google Scholar). Both MEK1 and MEK2 stably associate with ERK1/2, and this association is required for efficient activation of the latter in cells (15Xu B. Wilsbacher J.L. Collisson T. Cobb M.H. J. Biol. Chem. 1999; 274: 34029-34035Google Scholar, 16Tanoue T. Adachi M. Moriguchi T. Nishida E. Nat. Cell Biol. 2000; 2: 110-116Google Scholar). The binding site for ERK1/2 is located at the N terminus of MEK1/2 and consists of a short basic region known as the D domain (16Tanoue T. Adachi M. Moriguchi T. Nishida E. Nat. Cell Biol. 2000; 2: 110-116Google Scholar). MEK1 and MEK2 also contain a unique proline-rich insert between subdomains IX and X, which is required for full activation of ERK1/2 in intact cells (17Catling A.D. Schaeffer H.J. Reuter C.W. Reddy G.R. Weber M.J. Mol. Cell. Biol. 1995; 15: 5214-5225Google Scholar, 18Dang A. Frost J.A. Cobb M.H. J. Biol. Chem. 1998; 273: 19909-19913Google Scholar). The magnitude and duration of MAPK activation are important determinants of the cellular response to extracellular signals (19Marshall C.J. Cell. 1995; 80: 179-185Google Scholar,20Roovers K. Assoian R.K. Bioessays. 2000; 22: 818-826Google Scholar). Therefore, a tightly regulated balance between activation and inactivation mechanisms must exist to control the cellular activity of ERK1/2. Inactivation of the ERK1/2 enzymes is mainly achieved by dephosphorylation of the activating threonine and tyrosine residues. Biochemical and genetic studies have implicated both tyrosine-specific phosphatases and dual-specificity MAPK phosphatases in the negative regulation of ERK1/2 and other MAPKs (21Camps M. Nichols A. Arkinstall S. FASEB J. 2000; 14: 6-16Google Scholar, 22Keyse S.M. Curr. Opin. Cell Biol. 2000; 12: 186-192Google Scholar). Much less is known about the mechanisms that negatively regulate the pathway at the MAPKK level. The serine/threonine phosphatase protein phosphatase 2A was identified as the major phosphatase inactivating MEK1 in lysates of PC12 cells (23Alessi D.R. Gomez N. Moorhead G. Lewis T. Keyse S.M. Cohen P. Curr. Biol. 1995; 5: 283-295Google Scholar). Furthermore, overexpression of SV40 small t antigen, which binds to the A subunit of protein phosphatase 2A and inactivates the enzyme, was found to stimulate MEK and ERK activity in CV-1 cells (24Sontag E. Fedorov S. Kamibayashi C. Robbins D. Cobb M. Mumby M. Cell. 1993; 75: 887-897Google Scholar). It is not known whether protein phosphatase 2A activity for MEK1/2 is regulated. Feedback inhibition of MEK1/2 activity may also occur by direct phosphorylation. Several protein kinases, including Cdc2 (25Rossomando A.J. Dent P. Sturgill T.W. Marshak D.R. Mol. Cell. Biol. 1994; 14: 1594-1602Google Scholar), ERK1/2 (9Gotoh Y. Matsuda S. Takenaka K. Hattori S. Iwamatsu A. Ishikawa M. Kosako H. Nishida E. Oncogene. 1994; 9: 1891-1898Google Scholar, 26Brunet A. Pages G. Pouyssegur J. FEBS Lett. 1994; 346: 299-303Google Scholar, 27Saito Y. Gomez N. Campbell D.G. Ashworth A. Marshall C.J. Cohen P. FEBS Lett. 1994; 341: 119-124Google Scholar, 28Gardner A.M. Vaillancourt R.R. Lange-Carter C.A. Johnson G.L. Mol. Biol. Cell. 1994; 5: 193-201Google Scholar, 29Mansour S.J. Resing K.A. Candi J.M. Hermann A.S. Gloor J.W. Herskind K.R. Wartmann M. Davis R.J. Ahn N.G. J. Biochem. 1994; 116: 304-314Google Scholar), and Pak1 (30Frost J.A. Steen H. Shapiro P. Lewis T. Ahn N. Shaw P.E. Cobb M.H. EMBO J. 1997; 16: 6426-6438Google Scholar), have been shown to phosphorylate MEK1 at sites that are phosphorylated in intact cells. However, the impact of these phosphorylation events on the regulation of the ERK1/2 pathway remains uncertain. Here, we show that MEK1 is phosphorylated at Ser212 in intact cells. Substitution of Ser212with Ala enhanced the basal activity of MEK1 and MEK2, whereas phosphomimetic mutants completely inactivated the enzymes in vivo. We further show that mutations of the analogous Ser212 residue in the yeast MAPKKs Pbs2p and Ste7p similarly regulate their biological activity. Rat1 fibroblasts were cultured and synchronized by serum starvation as previously described (31Meloche S. J. Cell. Physiol. 1995; 163: 577-588Google Scholar). Rat1 cells were transfected with MEK1 expression plasmids using Lipofectin (Invitrogen). After 48 h, populations of stably transfected cells were selected by their ability to grow in complete minimum Eagle's medium containing 0.5 mg/ml Geneticin (Invitrogen). Human embryonic kidney (HEK) 293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and were growth-arrested by serum starvation for 24 h. The cells were transiently transfected by the calcium phosphate precipitation method. The sources of the plasmids used in this study were as follows: pGEX-2T/MEK2 (K.-L. Guan, University of Michigan, Ann Arbor, MI), pMT3-HA-SEK1 (J. Woodgett, Ontario Cancer Institute, Toronto, Canada), and pEF-Myc-MKK6 (A. Nebreda, European Molecular Biology Laboratory, Heidelberg, Germany). The plasmid pFA-Elk-1, which encodes a Gal4-Elk-1 fusion protein, and the Gal4-dependent luciferase reporter plasmid pFR-Luc were obtained from Stratagene. The XbaI/HindIII fragment of pGEX-MEK1, containing the entire human MEK1 coding sequence (32Meloche S. Gopalbhai K. Beatty B.G. Scherer S.W. Pellerin J. Cytogenet. Cell Genet. 2000; 88: 249-252Google Scholar), and theEcoRI/PvuII fragment of pGEX-MEK2 (33Zheng C.F. Guan K.-L. J. Biol. Chem. 1993; 268: 11435-11439Google Scholar), containing the human MEK2 coding sequence, were subcloned into pALTER-1 (Promega). To generate HA-tagged constructs of MEK1 and MEK2, a synthetic oligonucleotide encoding the amino acid sequence YDVPDYASL was inserted at the N terminus of the respective cDNAs (after the initiator methionine) using the Altered Sites in vitromutagenesis system (Promega). HA-MEK1 and HA-MEK2 cDNA constructs were then used as templates for in vitro mutagenesis to generate the various mutants described in this study. All mutations were confirmed by DNA sequencing. The HA-MEK1 and HA-MEK2 constructs were subcloned into the expression vector pRc/CMV (Invitrogen). Cell lysis, immunoprecipitation, and immunoblot analysis were performed as described previously (34Servant M.J. Coulombe P. Turgeon B. Meloche S. J. Cell Biol. 2000; 148: 543-556Google Scholar). Commercial antibodies were obtained from the following suppliers: anti-phospho-Ser218/Ser222MEK1/2 (Cell Signaling Technology) and anti-MEK1 (Transduction Laboratories). Monoclonal antibody 12CA5 raised against influenza was a gift from M. Dennis (SignalGene). Immunoblot analysis of MEK1/2 activating loop phosphorylation was carried out according to the manufacturer's specifications. The phosphotransferase activities of endogenous or ectopically expressed MEK1 and MEK2 were assayed by measuring their ability to increase the myelin basic protein kinase activity of recombinant ERK2 in vitro as previously described (35Gopalbhai K. Meloche S. J. Cell. Physiol. 1998; 174: 35-47Google Scholar). For reporter gene assays, 293 cells seeded in 24-well plates were cotransfected with 1 μg of pFR-Luc reporter construct, 50 ng of pFA-Elk-1, 300 ng of pCMV-β-gal, and 1 μg of MEK1 expression plasmids. The total DNA amount was kept constant at 3 μg with the pRc/CMV vector. After 48 h, the cells were harvested, and the activity of luciferase was assayed using a luciferase reporter assay kit (Promega). Transfection efficiency was normalized by measuring β-galactosidase activity. For analysis of phosphorylated peptides, 10 Petri dishes (100 mm) of HEK 293 cells were transfected with HA-MEK1, and two of the dishes were metabolically labeled for 6 h with 2 mCi/ml [32P]phosphoric acid. Cell lysates were prepared, and HA-MEK1 was immunoprecipitated as described above. The immunoprecipitated proteins were resolved by SDS-gel electrophoresis, and the gel was stained with Coomassie Brilliant Blue R-250 and exposed to x-ray film. The protein band corresponding to32P-labeled HA-MEK1 was excised from the gel, subjected to dithiothreitol reduction and iodoacetamide alkylation, and then digested overnight at 37 °C with 0.2 μg of sequencing-grade trypsin (Promega) (36Hellman U. Wernstedt C. Gonez J. Heldin C.H. Anal. Biochem. 1995; 224: 451-455Google Scholar). The tryptic peptides were extracted with 1% trifluoroacetic acid and 60% acetonitrile at 60 °C and separated by reverse-phase HPLC on a Vydac microbore C18 column using an Applied Biosystems 130A separation system. The column was developed at a flow rate of 150 μl/min using the following gradient program: 3 min in solvent A (0.1% trifluoroacetic acid in water), 0–50% solvent B (0.08% trifluoroacetic acid in 70% acetonitrile) during the next 60 min, and 50–100% solvent B during the remaining 7 min. The peptides were detected by absorbance at 220 nm, and the peaks were collected manually and subjected to Cerenkov counting to identify the radioactive phosphopeptides. Where necessary, HPLC-purified tryptic peptides were subjected to a second digestion with sequencing-grade endoproteinase Asp-N (Roche Molecular Biochemicals). The HPLC fractions were incubated for a total time of 5 h at 37 °C with two additions of 0.1 μg of Asp-N protease. The labeled peptides were applied to a Prosorb disc (Applied Biosystems) and subjected to automatic Edman degradation on a Procise Model 494 cLC sequencer using the general protocol of Hewick et al. (37Hewick R.M. Hunkapiller M.W. Hood L.E. Dreyer W.J. J. Biol. Chem. 1981; 256: 7990-7997Google Scholar). The phenylthiohydantoin-derivatives were analyzed on-line using an Applied Biosystems Model 140D capillary separation system and ultraviolet detection. The yeast strains used in this study were W303-1AΔste7(MAT a ade2 leu2 trp1 his3 ura3Δste7::LEU2) (B. Errede, University of North Carolina, Chapel Hill, NC), TM260 (MAT a ura3 leu2 trp1Δpbs2::LEU2) (H. Saito, Harvard Medical School, Boston, MA), YCW340 (MAT a ura3 leu2 his3 trp1 ssk2::LEU2 ssk22::LEU2 ste11::KanR), YCW365 (MAT a ura3 leu2 his3 trp1 ssk2::LEU2 ssk22::LEU2 ste50::TRP1) (38Wu C. Leberer E. Thomas D.Y. Whiteway M. Mol. Biol. Cell. 1999; 10: 2425-2440Google Scholar), and YGJ208 (MAT a ssk2::LEU2 ssk22::LEU2 sho1::TRP1) (this study). Yeast cells were transformed by the method described (39Schiestl R.H. Gietz R.D. Curr. Genet. 1989; 16: 339-346Google Scholar), and the plasmid-containing cells were identified on selective plates. Mating of Δste7 strains carrying the differentSTE7 mutant alleles with the wild-type tester strain DC17 (MATα his1) (laboratory collection) was performed for 7 h before replicating the cells onto plates selecting for diploids. Cells with different PBS2 mutant alleles were analyzed for osmosensitivity by transferring to rich medium containing 0.9 m NaCl and scoring growth after 3 days. The construction of both PBS2 andSTE7 plasmids and their mutant alleles was performed using the in vivo recombination procedure in the yeastSaccharomyces cerevisiae according to Jansen et al. 2G. Jansen, C. Wu, B. Schade, D. Y. Thomas, and M. Whitney, submitted for publication. Two backbone plasmids (low copy number) with the promoter region and the N-terminal part of either PBS2 or STE7 were first constructed: 1) pGREG506-PBS2-N, containing 701 bp of thePBS2 promoter region and the first 507 amino acids ofPBS2 coding sequence followed by an added uniqueNotI site and 2) pGREG506-STE7-N, containing 550 bp of theSTE7 promoter region and the first 352 amino acids ofSTE7 coding sequence followed by a NotI site. To generate the mutant plasmid constructs by the in vivorecombination procedure, the backbone plasmids were first digested withNotI and XhoI and co-transformed into the appropriate yeast strain with the respective C-terminal parts of the genes carrying the desired mutations generated by PCR with mutant primers. The resulting mutants were sequenced to confirm the desired mutation and subcloned into the Gal1-GST yeast expression vector pGREG546 to verify the expression of the mutant proteins by anti-GST immunoblot analysis. MEK1 is activated by phosphorylation at Ser218 and Ser222 in the regulatory loop between kinase subdomains VII and VIII. To better understand the regulation of MEK1 activity, we monitored the enzymatic activation and Ser218/Ser222 phosphorylation of MEK1 after serum stimulation of Rat1 fibroblasts. Detailed kinetic analysis revealed that MEK1 activation was very transient, reaching a peak at 5 min and returning to near basal levels by 15–30 min (Fig.1 A). A similar transient activation of endogenous MEK1/2 has been observed in other cell types (Ref. 23Alessi D.R. Gomez N. Moorhead G. Lewis T. Keyse S.M. Cohen P. Curr. Biol. 1995; 5: 283-295Google Scholar and data not shown). In contrast, the phosphorylation of activating Ser218/Ser222 residues, which was maximally induced at 3 min, was sustained for at least 3 h after serum addition (Fig. 1 B). These results indicate that mechanisms other than dephosphorylation of regulatory Ser218/Ser222 residues must contribute to inactivation of MEK1. Phosphopeptide mapping analysis has revealed that MEK1 is phosphorylated on multiple peptides in both quiescent and serum-stimulated cells (Refs. 17Catling A.D. Schaeffer H.J. Reuter C.W. Reddy G.R. Weber M.J. Mol. Cell. Biol. 1995; 15: 5214-5225Google Scholar and 26Brunet A. Pages G. Pouyssegur J. FEBS Lett. 1994; 346: 299-303Google Scholar and data not shown), suggesting that phosphorylation of residues other than the Ser218/Ser222 activation loop may also be involved in the regulation of the kinase. We initiated a series of experiments to identify new regulatory phosphorylation sites of MEK1. HEK 293 cells were transfected with HA-MEK1 and deprived of serum for 24 h. The cells were then metabolically labeled with [32P]orthophosphate for 5 h, and ectopically expressed MEK1 was immunoprecipitated with anti-HA antibody. After resolution by SDS-gel electrophoresis, the 32P-labeled MEK1 protein band was cut from the gel, alkylated, and subjected to complete in-gel trypsin digestion. The resulting tryptic peptides were separated by reverse-phase HPLC, and the fractions recovered were counted for radioactivity (Fig. 2 A). The radioactive fractions were subjected to automated Edman degradation, and the phenylthiohydantoin-derivatives were analyzed using a sensitive capillary separation system. The fraction eluting at 49 min was found to contain the peptide LCDFGVSGQLIDXMAN(S)FV, which corresponds to the tryptic fragment Leu206–Arg227 of the human MEK1 sequence (Fig. 2 A). This peptide contains four potential phosphorylation sites: Ser212, Ser218, Ser222, and Thr226. To refine our analysis, the HPLC fractions containing the Leu206–Arg227 fragment were pooled and subjected to a second digestion with endoproteinase Asp-N, which cleaves before aspartate residues. Analysis of Asp-N digestion product by HPLC revealed the presence of a major radioactive peak (Fig.2 B). N-terminal sequencing of this peak yielded the sequence DFG, which corresponds to the double-digested peptide Asp208–Ile216. The only phosphorylatable residue within this peptide is Ser212. These results unambiguously demonstrate that MEK1 is phosphorylated at Ser212 in vivo. Alignment of MAPKK sequences from different species revealed that Ser212, which lies in the activation loop between kinase subdomains VII and VIII, is conserved in all members of the MAPKK family from yeast to mammals (Fig.3). However, this residue is not found in Raf MAPKKKs, MAPKs, cyclin-dependent kinases, or cAMP-dependent protein kinase. Notably, replacement of Ser212 with aspartic acid was shown to completely abolish the basal kinase activity of MEK1 in vitro (40Mansour S.J. Candia J.M. Matsuura J.E. Manning M.C. Ahn N.G. Biochemistry. 1996; 35: 15529-15536Google Scholar). To evaluate the impact of Ser212 on the regulation of MEK1 activity in intact cells, we generated a series of MEK1 mutants by site-directed mutagenesis. The various HA-MEK1 constructs were transiently expressed in HEK 293 cells, and their phosphotransferase activity was measured using a specific ERK2 reactivation assay. Immunoblotting of total cell extracts with anti-HA antibody confirmed that all mutants were expressed to similar levels (Fig.4 A). Replacement of Ser212 with alanine significantly enhanced the enzymatic activity of MEK1 (from 3- to 5-fold) in exponentially growing HEK 293 cells, whereas mutation to the phosphomimetic acidic residue aspartate completely abolished it (Fig. 4 A). As previously reported, substitution of the activating phosphorylation sites Ser218and Ser222 with acidic residues (S218D/S222D) strongly potentiated the activity of MEK1, whereas substitution with alanine residues (S218A/S222A) impaired activation. Replacement of Ser212 with alanine did not further enhance the activity of the MEK1(S218D/S222D) mutant, nor did it rescue the compromised activation of the S218A/S222A mutant. However, substitution of Ser212 with aspartate completely abrogated the constitutive activation of the MEK1(S218D/S222D) mutant. We also tested whether the equivalent Ser216 residue of the related MAPKK MEK2 had similar regulatory effects. As shown in Fig. 4 B, replacement of Ser216 with alanine increased the basal activity of MEK2, whereas the aspartate mutation completely suppressed the activation of wild-type MEK2 and the constitutively activated MEK2(S222D/S226D) mutant.Figure 4Ser212 regulates the biological activity of MEK1 and MEK2. A and B, HEK 293 cells were transiently transfected with HA-tagged MEK1 or MEK2 constructs, respectively. After 48 h, the ectopically expressed MEK protein was immunoprecipitated with anti-HA antibody (α HA), and phosphotransferase activity was measured using an ERK2 reactivation assay. Expression of HA-tagged MEK1 and MEK2 proteins was analyzed by immunoblotting with anti-HA antibody.C, HEK 293 cells were transfected with expression plasmids for wild-type (wt) MEK1 or the indicated mutants in combination with Gal4-Elk-1 and the Gal4-dependent luciferase reporter gene. After 48 h, the activity of luciferase was measured and normalized to that of β-galactosidase. Results are presented as -fold activation over vector-transfected cells. All results are representative of four different experiments. MEK1 mutants:DD, S218D/S222D; AA, S218A/S222A; ADD, S212A/S218D/S222D; AAA, S212A/S218A/S222A; andDDD, S212D/S218D/S222D.View Large Image Figure ViewerDownload (PPT) To examine the functional consequences of MEK1 regulation by Ser212, we tested the ability of MEK1 mutants to potentiate the transcriptional activation of the ERK1/2 target Elk-1 in exponentially growing HEK 293 cells. Under these experimental conditions, Elk-1-dependent reporter activity was not significantly enhanced by expression of the wild-type MEK1 protein (Fig. 4 C). However, expression of the MEK1(S212A) mutant caused a small but reproducible 2-fold stimulation of Elk-1 transcriptional activity. In agreement with the results of enzymatic assays, transfection of activated MEK1(S218D/S222D) strongly potentiated Elk-1-dependent transcription, and this effect was completely prevented by substitution of Ser212 with a phosphomimetic Asp residue. To further investigate the role of Ser212 in the regulation of MEK1 activity, we generated populations of Rat1 fibroblasts stably expressing HA-MEK1 Ser212 mutants. The cells were made quiescent by serum starvation and restimulated for different period of times with serum, and the activity of ectopically expressed MEK1 was measured. Similar to the endogenous protein, activation of ectopic MEK1 was transient, reaching a peak at 5 min and returning to basal levels by 30 min (Fig. 5 A). The MEK1(S212A) mutant displayed constitutive activity in serum-deprived cells. Stimulation with serum induced a further increase in MEK1(S212A) activity at 5 min, which declined thereafter, but remained elevated for at least 24 h. Mutation of Ser212 to Asp lowered the basal activity of MEK1 and abrogated activation of the enzyme by serum growth factors. Immunoblot analysis confirmed that the mutants were expressed at levels comparable to the wild-type protein (Fig.5 B). These results are consistent with the idea that phosphorylation of Ser212 plays a role in the regulation of MEK1/2 activity and of downstream signaling events. MEK1 is activated by phosphorylation of Ser218/Ser222 in the activation loop. We therefore tested whether the effects of Ser212 mutations on MEK1 activity could be related to differences in activating phosphorylation of the kinase. For these studies, HA-MEK1 constructs were transiently expressed in HEK 293 cells. The cells were serum-starved and restimulated with serum for 5 min, and the phosphorylation of MEK1 at Ser218/Ser222 was analyzed by immunoblotting using a phospho-specific antibody. Mutation of Ser212 to Ala or Asp did not affect the phosphorylation of MEK1 at activating Ser218/Ser222 residues in serum-stimulated cells (Fig. 6 A). We also investigated whether Ser212 mutations interfere with the ability of MEK1 to bind its substrates ERK1 and ERK2. Cell extracts prepared from HEK 293 cells transiently transfected with HA-MEK1 constructs were incubated with His6-ERK2 beads, and the resulting complexes were analyzed by anti-HA immunoblotting. No differences were observed in the abilities of the various MEK1 mutants to bind ERK2 in this pull-down assay (Fig. 6 B). Similar results were obtained in co-immunoprecipitation experiments (data not shown). These observations indicate that Ser212 mutations are unlikely to alter the global three-dimensional structure of the MEK1 enzyme. They also demonstrate that the inactivation of MEK1 observed upon mutation of Ser212 to a phosphomimetic residue cannot be explained by inhibition of activating loop phosphorylation or by interference with substrate binding. To determine whether the inhibitory mechanism of MAPKK regulation by phosphorylation has been conserved during evolution, we extended our studies to the yeast S. cerevisiae STE7 and PBS2 MAPKK genes (41Gustin M.C. Albertyn J. Alexander M. Davenport K. Microbiol. Mol. Biol. Rev. 1998; 62: 1264-1300Google Scholar). TheSTE7 and PBS2 gene products, Ste7p and Pbs2p, display significant amino acid sequence identity to mammalian MEK1/2. Ser212 in MEK1 corresponds to Ser353 in Ste7p and Ser508 in Pbs2p (Fig. 3). Mutations of the corresponding serine residues in Ste7p and Pbs2p were made by site-directed mutagenesis, and the resulting mutants were subcloned into a low copy yeast shuttle plasmid vector by in vivorecombination in yeast. The function of these alleles was tested in yeast strain W303-1AΔste7 for STE7-related functions and in yeast strain TM260 for PBS2-related functions. The mating ability of the yeast S. cerevisiae requires the function of Ste7p. Strain W303-1AΔste7 has no functionalSTE7 and therefore is unable to mate with a partner of opposite mating type. Transformation of the wild-type STE7gene into strain W303-1AΔste7 restores the mating ability of the cells, whereas the empty vector does not. Mutation of Ste7p Ser353 to alanine had no significant effect on mating efficiency (Fig. 7 A). However, substitution of Ser353 with a phosphomimetic aspartate residue led to a sterile phenotype, suggesting that Ste7p(S353D) is nonfunctional. To rule out the possibility that Ste7p(S353D) is not expressed or has decreased stability, the wild-type and mutant versions of Ste7p were expressed in yeast as GST fusion proteins and analyzed by immunoblotting. The results confirm that both the S353D and S353A mutants have steady-state levels of expression similar to those of wild-type Ste7p (data not shown). Corresponding mutations were also made in the PBS2 gene. The Pbs2p signaling pathway is required for the hyperosmolarity stress response, and cells defective in Pbs2p function are unable to grow on hyperosmotic medium. The sensitive yeast strain TM260 was transformed with different alleles of PBS2, and the transformants were tested for their ability to grow on hyperosmotic medium. Wild-type Pbs2p allowed the growth of the hyperosmolarity-sensitive cells on medium containing 0.9 m NaCl, and the S508A mutant displayed a similar phenotype (Fig. 7 A). In contrast, replacement of Ser508 with an aspartate residue blocked the growth of TM260 cells on hyperosmotic medium, suggesting that the S508D mutation, similar to the corresponding mutation in STE7, results in a nonfunctional allele of the MAPKK protein. This loss of function was not due to differences in expression levels, as both wild-type and mutant Pbs2p-GST fusion proteins were expressed at comparable levels (data not shown). It has been shown that substitution of Ser514 and Thr518 with phosphomimetic amino acid residues (either Glu or Asp) leads to constitutively activated forms of Pbs2p (42Bilsland-Marchesan E. Arino J. Saito H. Sunnerhagen P. Posas F. Mol. Cell. Biol. 2000; 20: 3887-3895Google Scholar). We changed these two residues to aspartate residues to obtain a constitutively activated Pbs2p kinase (Pbs2p(S514D/T518D)). Unlike wild-type Pbs2p, whose activity requires at least one of the upstream activating kinases Ssk2p, Ssk22p, or Ste11p, Pbs2p(S514D/T518D) was able to activate the HOG pathway independent of these activating kinases. To assess the regulatory effect of Ser508 on the constitutively activated Pbs2p(S514D/T518D) mutant, substitution of Ser508 with either Ala or Asp was made in combination with the S514D/T518D mutation. The resulting constructs were transformed into strains YCW340 (Δssk2 Δssk22 Δste11), YCW365 (Δssk2 Δssk22 Δste50), and YGJ208 (Δssk2 Δssk22 Δsho1) and tested for activation of the HOG pathway. As shown in Fig.7 B, the S508D mutation completely blocked the ability of Pbs2p(S514D/T518D) to activate the HOG pathway, whereas no significant effect of the S508A mutation was observed on Pbs2p(S514D/T518D) activity. These results indicate that the regulatory effect of Ser508 is dominant over the effect of activating phosphorylation of Pbs2p at Ser514 and Thr518. To test whether mutation of the dominant inhibitory phosphorylation site Ser508 to alanine is sufficient to render Pbs2p constitutively activated, wild-type Pbs2p, Pbs2p(S508A), and Pbs2p(S508D) were transformed into strains YCW340, YCW365, and YGJ208 and assayed for activation of the HOG pathway. As expected, no HOG pathway activity was observed in any strain transformed with Pbs2p(S508D) under all conditions tested (Fig. 7 B). This is consistent with previous observations thatSHO1-STE11/STE50 signaling is essential in the absence of the SLN1 two-component osmosensor branch that activates the MAPKKKs Ssk2p and Ssk22p (38Wu C. Leberer E. Thomas D.Y. Whiteway M. Mol. Biol. Cell. 1999; 10: 2425-2440Google Scholar, 43Posas F. Saito H. Science. 1997; 276: 1702-1705Google Scholar). However, Pbs2p(S508A) displayed a significant increase inSHO1-independent HOG pathway activity, as judged by the ability of cells to grow in medium containing 0.9 m NaCl. However, this activity was not observed when either STE11 orSTE50 was deleted in the absence of SSK2 andSSK22. Thus, the HOG pathway activity observed wasSHO1-independent, but STE11- andSTE50-dependent. Enzymatic activation of MEK1 requires phosphorylation of Ser218 and Ser222 in the activation loop (7Alessi D.R. Saito Y. Campbell D.G. Cohen P. Sithanandam G. Rapp U. Ashworth A. Marshall C.J. Cowley S. EMBO J. 1994; 13: 1610-1619Google Scholar,8Zheng C.F. Guan K.-L. EMBO J. 1994; 13: 1123-1131Google Scholar). However, the mechanisms responsible for MEK1/2 inactivation remain to be established. Our observation that sustained phosphorylation of MEK1 at regulatory Ser218/Ser222 residues contrasts with the transient nature of MEK1 activation in Rat1 fibroblasts led us to believe that mechanisms other than the simple involvement of protein phosphatases are involved in MEK1 inactivation. MEK1 is phosphorylated on multiple peptides in cells, suggesting that phosphorylation of residues other than Ser218 and Ser222 might be involved in other aspects of MEK1 regulation (17Catling A.D. Schaeffer H.J. Reuter C.W. Reddy G.R. Weber M.J. Mol. Cell. Biol. 1995; 15: 5214-5225Google Scholar, 26Brunet A. Pages G. Pouyssegur J. FEBS Lett. 1994; 346: 299-303Google Scholar). Here, we have reported that MEK1 is phosphorylated at Ser212 in intact cells. Importantly, we have provided biochemical and genetic evidence that phosphorylation of the equivalent Ser212 residue in human MEK1 and MEK2 and in the yeast MAPKKs Ste7p and Pbs2p negatively regulates enzymatic activity in vivo. These findings suggest that both activation and inactivation of MAPKK family members are mediated by common evolutionarily conserved mechanisms. Replacement of Ser212 with acidic residues does not prevent activating phosphorylation of MEK1 at Ser218/Ser222, nor does it affect binding to ERK2 substrate, thereby suggesting that Ser212phosphorylation may directly interfere with the catalytic reaction. Consistent with this hypothesis, a previous study has shown that substitution of Ser212 with aspartate completely abolishes the basal kinase activity of MEK1 for exogenous substrates in vitro (40Mansour S.J. Candia J.M. Matsuura J.E. Manning M.C. Ahn N.G. Biochemistry. 1996; 35: 15529-15536Google Scholar). Conversely, replacement of Ser212 was alanine was shown to increase the rate of autophosphorylation of recombinant MEK1 (44Xu S. Robbins D. Frost J. Dang A. Lange-Carter C. Cobb M.H. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 6808-6812Google Scholar) and to enhance the basal phosphotransferase activity of MEK1-GST by 3–4-fold (8Zheng C.F. Guan K.-L. EMBO J. 1994; 13: 1123-1131Google Scholar) in in vitro kinase assays. We also observed that the equivalent S212A mutation significantly increases the enzymatic activity of MEK1 and MEK2 in intact cells (Fig. 4). It is noteworthy that Ser212 is localized within the activation loop of MEK1, close to the activating phosphorylation sites. Although Ser212 phosphorylation does not interfere with phosphorylation of Ser218/Ser222, the presence of an additional phosphate group might compete for or establish undesirable electrostatic interactions with one or more basic residues in the catalytic domain. Thus, Ser212 phosphorylation may hinder the correct positioning of the aspartate residue essential for catalysis or perturb the conformation of the activation loop, blocking access of the substrate to the active site. Given the evolutionarily conserved nature of the MAPKK family, elucidation of the crystal structure of MEK1 in the inactive and active conformations will add greatly to our understanding of the mechanisms controlling both activation and inactivation of this family of enzymes. Studies by different groups have shown that MEK1 is also phosphorylated at Thr292, Ser298, and Thr386 in vivo (9Gotoh Y. Matsuda S. Takenaka K. Hattori S. Iwamatsu A. Ishikawa M. Kosako H. Nishida E. Oncogene. 1994; 9: 1891-1898Google Scholar, 25Rossomando A.J. Dent P. Sturgill T.W. Marshak D.R. Mol. Cell. Biol. 1994; 14: 1594-1602Google Scholar, 26Brunet A. Pages G. Pouyssegur J. FEBS Lett. 1994; 346: 299-303Google Scholar, 27Saito Y. Gomez N. Campbell D.G. Ashworth A. Marshall C.J. Cohen P. FEBS Lett. 1994; 341: 119-124Google Scholar, 28Gardner A.M. Vaillancourt R.R. Lange-Carter C.A. Johnson G.L. Mol. Biol. Cell. 1994; 5: 193-201Google Scholar, 30Frost J.A. Steen H. Shapiro P. Lewis T. Ahn N. Shaw P.E. Cobb M.H. EMBO J. 1997; 16: 6426-6438Google Scholar). However, the exact biological consequences of these phosphorylation events remain to be established. It has been suggested that the MAPKs ERK1 and ERK2 phosphorylate MEK1 at Thr292/Thr386 and inhibit its activation by a negative feedback mechanism (26Brunet A. Pages G. Pouyssegur J. FEBS Lett. 1994; 346: 299-303Google Scholar). In contrast, another study reported that the MEK1(T292A) mutant is inactivated more rapidly than wild-type MEK1 in serum-stimulated cells (17Catling A.D. Schaeffer H.J. Reuter C.W. Reddy G.R. Weber M.J. Mol. Cell. Biol. 1995; 15: 5214-5225Google Scholar). We did not observe any effect of the T292A mutation on MEK1 activity in exponentially growing 293 cells (data not shown). In a more recent study, it was reported that Akt phosphorylates MKK4 at Ser78 and negatively regulates its activity by interfering with substrate binding (45Park H.S. Kim M.S. Huh S.H. Park J. Chung J. Kang S.S. Choi E.J. J. Biol. Chem. 2002; 277: 2573-2578Google Scholar). MKK4 is the only member of the mammalian MAPKK family that has a consensus Akt phosphorylation motif. It is likely that MAPKKs are regulated by phosphorylation mechanisms common to all members as well as by more subtle mechanisms that allow differential regulation of individual isoforms. Identification of the physiological kinases and phosphatases that control the phosphorylation level of Ser212 and other regulatory sites will be necessary for a complete understanding of MAPKK regulation. We thank J. Noel and M. Arcand for technical assistance; M. H. Cobb, K.-L. Guan, A. Nebreda, and J. Woodgett for reagents; and H. Saito and B. Errede for strains." @default.
• W2056547069 created "2016-06-24" @default.
• W2056547069 creator A5000249682 @default.
• W2056547069 creator A5032742659 @default.
• W2056547069 creator A5059796808 @default.
• W2056547069 creator A5061447684 @default.
• W2056547069 creator A5063827931 @default.
• W2056547069 creator A5074225868 @default.
• W2056547069 creator A5085198110 @default.
• W2056547069 date "2003-03-01" @default.
• W2056547069 modified "2023-10-01" @default.
• W2056547069 title "Negative Regulation of MAPKK by Phosphorylation of a Conserved Serine Residue Equivalent to Ser212 of MEK1" @default.
• W2056547069 cites W137936598 @default.
• W2056547069 cites W1479869774 @default.
• W2056547069 cites W1566737177 @default.
• W2056547069 cites W1572416479 @default.
• W2056547069 cites W1577992990 @default.
• W2056547069 cites W1600871831 @default.
• W2056547069 cites W1848239201 @default.
• W2056547069 cites W1899552864 @default.
• W2056547069 cites W1965287062 @default.
• W2056547069 cites W1966260349 @default.
• W2056547069 cites W1967780354 @default.
• W2056547069 cites W1974140472 @default.
• W2056547069 cites W1983475354 @default.
• W2056547069 cites W1985001103 @default.
• W2056547069 cites W1995819749 @default.
• W2056547069 cites W1997656209 @default.
• W2056547069 cites W1999676041 @default.
• W2056547069 cites W2000290369 @default.
• W2056547069 cites W2001521752 @default.
• W2056547069 cites W2005026826 @default.
• W2056547069 cites W2005941786 @default.
• W2056547069 cites W2009916885 @default.
• W2056547069 cites W2016071419 @default.
• W2056547069 cites W2020184457 @default.
• W2056547069 cites W2022524230 @default.
• W2056547069 cites W2027624022 @default.
• W2056547069 cites W2054937093 @default.
• W2056547069 cites W205686078 @default.
• W2056547069 cites W2067524077 @default.
• W2056547069 cites W2083117403 @default.
• W2056547069 cites W2084765883 @default.
• W2056547069 cites W2084952038 @default.
• W2056547069 cites W2085136839 @default.
• W2056547069 cites W2098719212 @default.
• W2056547069 cites W2105229705 @default.
• W2056547069 cites W2110966930 @default.
• W2056547069 cites W2111305451 @default.
• W2056547069 cites W2136623592 @default.
• W2056547069 cites W2140490890 @default.
• W2056547069 cites W2148519196 @default.
• W2056547069 cites W2152146770 @default.
• W2056547069 cites W2162322742 @default.
• W2056547069 doi "https://doi.org/10.1074/jbc.m211870200" @default.
• W2056547069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12506122" @default.
• W2056547069 hasPublicationYear "2003" @default.
• W2056547069 type Work @default.
• W2056547069 sameAs 2056547069 @default.
• W2056547069 citedByCount "37" @default.
• W2056547069 countsByYear W20565470692012 @default.
• W2056547069 countsByYear W20565470692013 @default.
• W2056547069 countsByYear W20565470692014 @default.
• W2056547069 countsByYear W20565470692015 @default.
• W2056547069 countsByYear W20565470692016 @default.
• W2056547069 countsByYear W20565470692019 @default.
• W2056547069 countsByYear W20565470692021 @default.
• W2056547069 countsByYear W20565470692023 @default.
• W2056547069 crossrefType "journal-article" @default.
• W2056547069 hasAuthorship W2056547069A5000249682 @default.
• W2056547069 hasAuthorship W2056547069A5032742659 @default.
• W2056547069 hasAuthorship W2056547069A5059796808 @default.
• W2056547069 hasAuthorship W2056547069A5061447684 @default.
• W2056547069 hasAuthorship W2056547069A5063827931 @default.
• W2056547069 hasAuthorship W2056547069A5074225868 @default.
• W2056547069 hasAuthorship W2056547069A5085198110 @default.
• W2056547069 hasBestOaLocation W20565470691 @default.
• W2056547069 hasConcept C11960822 @default.
• W2056547069 hasConcept C185592680 @default.
• W2056547069 hasConcept C2776414213 @default.
• W2056547069 hasConcept C2781338088 @default.
• W2056547069 hasConcept C55493867 @default.
• W2056547069 hasConcept C86803240 @default.
• W2056547069 hasConcept C95444343 @default.
• W2056547069 hasConceptScore W2056547069C11960822 @default.
• W2056547069 hasConceptScore W2056547069C185592680 @default.
• W2056547069 hasConceptScore W2056547069C2776414213 @default.
• W2056547069 hasConceptScore W2056547069C2781338088 @default.
• W2056547069 hasConceptScore W2056547069C55493867 @default.
• W2056547069 hasConceptScore W2056547069C86803240 @default.
• W2056547069 hasConceptScore W2056547069C95444343 @default.
• W2056547069 hasIssue "10" @default.
• W2056547069 hasLocation W20565470691 @default.
• W2056547069 hasOpenAccess W2056547069 @default.
• W2056547069 hasPrimaryLocation W20565470691 @default.
• W2056547069 hasRelatedWork W1978122481 @default.
• W2056547069 hasRelatedWork W1979787995 @default.
• W2056547069 hasRelatedWork W1992092364 @default.

• next